Clinical Trial Update: Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years [Phase 3]

View source ↗

Summary

Phase 3 study of an investigational quadrivalent meningococcal conjugate vaccine in children aged 2 to 9 years has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infections
• Meningococcal Meningitis

Drugs mentioned

• Investigational quadrivalent meningococcal conjugate vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2020-06-09